“老牌”外企在自贸港有了新梦想

Core Viewpoint - The opening of the Hainan Free Trade Port marks a new beginning for Hainan Zhanbang Pharmaceutical Co., Ltd., allowing the company to benefit from favorable policies and expand its operations significantly [2][3]. Group 1: Company Overview - Hainan Zhanbang Pharmaceutical, established in 1988, is a wholly foreign-owned pharmaceutical enterprise invested by the Italian Zhanbang Group, with a focus on various therapeutic areas including respiratory diseases, urological diseases, and cardiovascular conditions [3]. - The company has experienced rapid growth since the establishment of the Hainan Free Trade Port, with annual output value increasing from 20-30 million yuan to over 500 million yuan [3]. Group 2: Policy Benefits - The company is benefiting from the processing and value-added domestic sales tax exemption policy, with products such as acetylcysteine granules and arginine ibuprofen granules included in the tax exemption [3]. - Hainan Zhanbang Pharmaceutical imported two production equipment units under the "zero tariff" policy, resulting in a tax reduction of approximately 2 million yuan, which has lowered production costs and enhanced market competitiveness [3]. Group 3: Future Plans - The company plans to invest over 15 million yuan next year to introduce new packaging production line equipment through the "zero tariff" policy, which is expected to increase production capacity by more than 50% [4].